<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> consumption is inversely associated with the risk of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, suggesting a neuroprotective effect </plain></SENT>
<SENT sid="1" pm="."><plain>In a rat model of transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, we identified <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> as a possible treatment for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Sprague-Dawley rats were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 2 hours </plain></SENT>
<SENT sid="3" pm="."><plain>Five sets of experiments were conducted: to determine the dose-response effect of <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> on <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and functional outcome; to determine whether combining <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> produces synergistic neuroprotection; to determine the therapeutic windows of opportunity for <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> in <z:hpo ids='HP_0001297'>stroke</z:hpo>; to test whether <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> promotes <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> in a hemorrhagic or <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or after administration of thrombolytics; and to test the affect of <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> on <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α protein expression </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> at 1.5 g/kg reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and behavioral dysfunction when administered at 2, 3, or 4 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The protective effect of <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> was not improved when paired with <z:hpo ids='HP_0002045'>hypothermia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> did not promote <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> in hemorrhagic or <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in combination with recombinant tissue-type plasminogen activator or urokinase </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> treatment (1.5 g/kg) increased protein levels of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α at 3 hours postreperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> exerts a strong neuroprotective effect when administered up to 4 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, increases expression of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α, and does not promote <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> when used with thrombolytics </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> is a potential neuroprotectant for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>